GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Stock Based Compensation

NeuBase Therapeutics (STU:O7P) Stock Based Compensation : €-0.22 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Stock Based Compensation?

NeuBase Therapeutics's Stock Based Compensation for the three months ended in Sep. 2023 was €-0.27 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.22 Mil.


NeuBase Therapeutics Stock Based Compensation Historical Data

The historical data trend for NeuBase Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Stock Based Compensation Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 - 8.14 4.41 3.15

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 -0.48 0.30 0.23 -0.27

NeuBase Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.22 Mil.


NeuBase Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (STU:O7P) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines